Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trial

Paul Crawford; Amanda Crawford; Frederick Nielson; Robert Lystrup

doi:10.1016/j.ctim.2019.05.022

Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trial

Paul Crawford, Amanda Crawford, Frederick Nielson, Robert Lystrup

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

OBJECTIVE: To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain.

DESIGN: We carried out a subgroup analysis on data from a randomized, double-blind, placebo-controlled trial, "The use of Methylsulfonylmethane (MSM) in the treatment of low back pain," to determine the safety of taking 6 g daily of MSM (OptiMSM®, Bergstrom Nutrition). We monitored metabolic parameters to determine whether MSM altered hematologic, liver or kidney function. We also monitored physiologic parameters of blood pressure and weight.

SETTING: Family Medicine Residency, Mike O'Callaghan Military Medical Center.

MAIN OUTCOME MEASURES: Metabolic parameters as measured by hematologic function - white blood cells (WBC), platelets, hemoglobin (Hb), glucose; liver function as measured by - total bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Physiologic parameters as measured by weight, diastolic (DBP) and systolic blood pressure (SBP); kidney function as measured by creatinine.

RESULTS: Analysis of outcome measures showed no significant difference between MSM and placebo (p < 0.05) safety values.

CONCLUSION: MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study.

Original language	English
Pages (from-to)	85-88
Number of pages	4
Journal	Complementary therapies in medicine
Volume	45
DOIs	https://doi.org/10.1016/j.ctim.2019.05.022
State	Published - Aug 2019
Externally published	Yes

Keywords

Adult
Blood/drug effects
Blood Pressure/drug effects
Dimethyl Sulfoxide/therapeutic use
Double-Blind Method
Female
Humans
Kidney/drug effects
Liver/drug effects
Low Back Pain/drug therapy
Male
Middle Aged
Osteoarthritis/drug therapy
Sulfones/therapeutic use

Access to Document

10.1016/j.ctim.2019.05.022

Cite this

@article{0664234e0c3c47c2ac4842ae6c6de0c3,

title = "Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trial",

abstract = "OBJECTIVE: To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain.DESIGN: We carried out a subgroup analysis on data from a randomized, double-blind, placebo-controlled trial, {"}The use of Methylsulfonylmethane (MSM) in the treatment of low back pain,{"} to determine the safety of taking 6 g daily of MSM (OptiMSM{\textregistered}, Bergstrom Nutrition). We monitored metabolic parameters to determine whether MSM altered hematologic, liver or kidney function. We also monitored physiologic parameters of blood pressure and weight.SETTING: Family Medicine Residency, Mike O'Callaghan Military Medical Center.MAIN OUTCOME MEASURES: Metabolic parameters as measured by hematologic function - white blood cells (WBC), platelets, hemoglobin (Hb), glucose; liver function as measured by - total bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Physiologic parameters as measured by weight, diastolic (DBP) and systolic blood pressure (SBP); kidney function as measured by creatinine.RESULTS: Analysis of outcome measures showed no significant difference between MSM and placebo (p < 0.05) safety values.CONCLUSION: MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study.",

keywords = "Adult, Blood/drug effects, Blood Pressure/drug effects, Dimethyl Sulfoxide/therapeutic use, Double-Blind Method, Female, Humans, Kidney/drug effects, Liver/drug effects, Low Back Pain/drug therapy, Male, Middle Aged, Osteoarthritis/drug therapy, Sulfones/therapeutic use",

author = "Paul Crawford and Amanda Crawford and Frederick Nielson and Robert Lystrup",

note = "Published by Elsevier Ltd.",

year = "2019",

month = aug,

doi = "10.1016/j.ctim.2019.05.022",

language = "English",

volume = "45",

pages = "85--88",

journal = "Complementary therapies in medicine",

issn = "0965-2299",

}

TY - JOUR

T1 - Methylsulfonylmethane for treatment of low back pain

T2 - A safety analysis of a randomized, controlled trial

AU - Crawford, Paul

AU - Crawford, Amanda

AU - Nielson, Frederick

AU - Lystrup, Robert

N1 - Published by Elsevier Ltd.

PY - 2019/8

Y1 - 2019/8

N2 - OBJECTIVE: To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain.DESIGN: We carried out a subgroup analysis on data from a randomized, double-blind, placebo-controlled trial, "The use of Methylsulfonylmethane (MSM) in the treatment of low back pain," to determine the safety of taking 6 g daily of MSM (OptiMSM®, Bergstrom Nutrition). We monitored metabolic parameters to determine whether MSM altered hematologic, liver or kidney function. We also monitored physiologic parameters of blood pressure and weight.SETTING: Family Medicine Residency, Mike O'Callaghan Military Medical Center.MAIN OUTCOME MEASURES: Metabolic parameters as measured by hematologic function - white blood cells (WBC), platelets, hemoglobin (Hb), glucose; liver function as measured by - total bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Physiologic parameters as measured by weight, diastolic (DBP) and systolic blood pressure (SBP); kidney function as measured by creatinine.RESULTS: Analysis of outcome measures showed no significant difference between MSM and placebo (p < 0.05) safety values.CONCLUSION: MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study.

AB - OBJECTIVE: To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain.DESIGN: We carried out a subgroup analysis on data from a randomized, double-blind, placebo-controlled trial, "The use of Methylsulfonylmethane (MSM) in the treatment of low back pain," to determine the safety of taking 6 g daily of MSM (OptiMSM®, Bergstrom Nutrition). We monitored metabolic parameters to determine whether MSM altered hematologic, liver or kidney function. We also monitored physiologic parameters of blood pressure and weight.SETTING: Family Medicine Residency, Mike O'Callaghan Military Medical Center.MAIN OUTCOME MEASURES: Metabolic parameters as measured by hematologic function - white blood cells (WBC), platelets, hemoglobin (Hb), glucose; liver function as measured by - total bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Physiologic parameters as measured by weight, diastolic (DBP) and systolic blood pressure (SBP); kidney function as measured by creatinine.RESULTS: Analysis of outcome measures showed no significant difference between MSM and placebo (p < 0.05) safety values.CONCLUSION: MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study.

KW - Adult

KW - Blood/drug effects

KW - Blood Pressure/drug effects

KW - Dimethyl Sulfoxide/therapeutic use

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Kidney/drug effects

KW - Liver/drug effects

KW - Low Back Pain/drug therapy

KW - Male

KW - Middle Aged

KW - Osteoarthritis/drug therapy

KW - Sulfones/therapeutic use

U2 - 10.1016/j.ctim.2019.05.022

DO - 10.1016/j.ctim.2019.05.022

M3 - Article

C2 - 31331587

SN - 0965-2299

VL - 45

SP - 85

EP - 88

JO - Complementary therapies in medicine

JF - Complementary therapies in medicine

ER -

Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this